Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

  • 1,
  • 1,
  • 1,
  • 1,
  • 1, 2,
  • 4,
  • 5,
  • 1, 3,
  • 1, 3,
  • 1, 2 and
  • 1Email author
Contributed equally
BMC Cancer201717:220

https://doi.org/10.1186/s12885-017-3210-z

Received: 5 October 2016

Accepted: 21 March 2017

Published: 27 March 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
5 Oct 2016 Submitted Original manuscript
10 Oct 2016 Author responded Author comments - Emilie Lereclus
Resubmission - Version 2
10 Oct 2016 Submitted Manuscript version 2
28 Oct 2016 Reviewed Reviewer Report - Alan Lefor
17 Nov 2016 Reviewed Reviewer Report - Kjersti Flatmark
21 Dec 2016 Author responded Author comments - Emilie Lereclus
Resubmission - Version 3
21 Dec 2016 Submitted Manuscript version 3
9 Jan 2017 Reviewed Reviewer Report - Kjersti Flatmark
7 Feb 2017 Author responded Author comments - Emilie Lereclus
Resubmission - Version 4
7 Feb 2017 Submitted Manuscript version 4
5 Mar 2017 Reviewed Reviewer Report - Kjersti Flatmark
13 Mar 2017 Author responded Author comments - Emilie Lereclus
Resubmission - Version 5
13 Mar 2017 Submitted Manuscript version 5
Publishing
21 Mar 2017 Editorially accepted
27 Mar 2017 Article published 10.1186/s12885-017-3210-z

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Université François-Rabelais de Tours, CNRS, GICC UMR 7292, UFR de médecine, BP 3223, Tours Cedex 01, France
(2)
CHRU de Tours, Department of Hepato-Gastroenterology and Digestive Oncology, Tours, France
(3)
CHRU de Tours, Laboratory of Pharmacology-Toxicology, Tours, France
(4)
INSERM, UMR 1098, Department of Medical Oncology, University Hospital, Besançon, France
(5)
Department of Hepato-Gastroenterology and Digestive Oncology, University Hospital Robert Debré, Reims, France

Advertisement